Quick Answer
Autolus Therapeutics plc reported Revenue From Contract With Customer Excluding Assessed Tax of $75.39 million for the year ending 2025.
- Autolus Therapeutics plc showed an increase of +644.9% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Autolus Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2024: $0.00 | Q3 2024: $0.00 | Q2 2025: $20.92 million | Q3 2025: $21.19 million.
- Historical annual values: Fiscal year 2025: $75.39 million | Fiscal year 2024: $10.12 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: